[{"orgOrder":0,"company":"University of Alberta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belnacasan","moa":"Caspase-1","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"University of Alberta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Alberta \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for L-Prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-l-valyl-N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)-

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Alberta

                          Country arrow
                          Compamed
                          Not Confirmed

                          University of Alberta

                          Country arrow
                          Compamed
                          Not Confirmed

                          Details : A team of researchers from the university of Alberta have identified a drug called VX-765 as a strong candidate therapy for MS patients.

                          Brand Name : VX-765

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 03, 2020

                          Lead Product(s) : Belnacasan

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank